A clinical trial led by the National Cancer Institute (NCI), part of the National Institutes of Health, has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS). The immunotherapy drug atezolizumab (Tecentriq) was recently approved by the U.S. Food and Drug Administration (FDA)(link is external) for the treatment of adults and
Now the U.S. is dealing with a new X-factor. Actually, it’s an XBB-factor: the XBB.1.5 Omicron subvariant. The XBB.1.5 comprised an estimated 40.5% of all Covid-19 cases over this past week, based on data from the Centers for Disease Control and Prevention (CDC). That’s up from 21.7% the week prior. That one week jump has vaulted
An innovative immunotherapy combination has shown a stunning 99% response rate in children with relapsed leukemia. The phase 2 trial, run jointly between researchers at St. Jude Children’s Research Hospital in Memphis and Shanghai Children’s Hospital in China tested the therapy in 225 children who had relapsed after conventional treatment. The work published in the Journal
China is predicted to see two peaks in cases as COVID-19 spreads throughout the country, the first peak in mid-January and the second in early March. New modelling by Airfinity has examined data from China’s regional provinces. The current outbreak is growing more rapidly in some regions than in others. Cases are currently rising much
New immunotherapies can allow healing cells to be activated or deactivated according to the stage of the disease, while more accurately targeting tumors While CAR T therapy represents one of the most impressive innovations in cancer care, the treatment can cause autoimmune-like side effects. Many have contended with the dilemma of maximizing the therapy’s benefits
Pfizer announced positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene elaparvovec, an investigational gene therapy, for the treatment of adult males with moderately severe to severe hemophilia B. The BENEGENE-2 study met its primary endpoint of non-inferiority and superiority in the annualized bleeding rate (ABR) of total bleeds post-fidanacogene elaparvovec infusion
Tel Aviv University researchers monitored the physiological data of close to 5,000 Israelis over two years In a first-of-its-kind study, researchers at Tel Aviv University equipped close to 5,000 Israelis with smartwatches and monitored their physiological parameters over two years. Of those monitored, 2,038 received the booster dose of the coronavirus vaccine, allowing the researchers
1) Mapping the hurdles for the clinical applications of Advanced Therapy Medicinal Products (ATMPs) Deadline model single-stage Planned opening date 12 January 2023 Deadline date 13 April 2023 17:00:00 Brussels time ExpectedOutcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 6 “Maintaining an innovative,
Single stage with dead-line 15 march 2023 ExpectedOutcome: Research and innovation (R&I) actions to be supported under this topic must work towards results that contribute to all the following expected outcomes. Scope: There are over 7 000 rare diseases resulting in 30 million patients1 in Europe with a rare disease. Globally more than 300 million patients2 are
Implantable platform provides prolonged treatment of Type 1 diabetes A quarter-sized device created at Houston Methodist could drastically alter the course of treatment for Type 1 diabetes, a chronic condition that impacts millions of Americans and does not have a cure. In a study published in the Dec. 26 issue of Nature Communications, a research team led
